Analystreport

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $27.00 price target on the stock.

Catalyst Pharmaceuticals, Inc.  (CPRX) 
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.catalystpharma.com